Clinical trial · Interventional
Effect of ESPB on Postoperative Pain in Patients With Breast Cancer Implant Reconstruction
Effect of Erector Spinae Plane Block on Postoperative Pain in Patients With Breast Cancer Implant Reconstruction
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Nowadays, the incidence of breast cancer is the first number of malignant tumors, and the primary treatment method is surgery.With the development of medical technology and concept, radical mastectomy combined breast reconstruction are becoming more and more popular.But the reconstruction caused greater trauma and more severe postoperative pain.ESPB is a new nerve block method which thought to reduce pain after thoracic and breast surgery.However, there are few studies on radical mastectomy combined breast reconstruction. So, this randomized controlled study is conducted to explore its impact on postoperative pain and thus provide more data guidance for clinical.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Erector Spinae Plane Block | — | UNRESOLVED | — |
| Mammary Cancer | — | UNRESOLVED | — |
| Postoperative Pain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Erector spinae plane block | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Erector spinae plane block group
- description
- Before surgery, an ultrasound-guided ESPB was performed. 30 mL of 0.375% ropivacaine and 0.5μ g/kg dexmedetomidine mixture was injected in the interfascial plane between rhomboideus major and erector spinae muscle. Ropivacaine is produced by AstraZeneca AB under the trade name of Naropin, and the specifications are 75 mg / 10 ml. Dexmedetomidine is produced by HengRui medical China and the specifications are 100μg / 1 ml。
- interventionNames
- Procedure: Erector spinae plane block
- type
- NO_INTERVENTION
- label
- Control group
- description
- Control groups do not receive additional analgesia.
Primary outcomes (1)
- measure
- Post-operative acute pain score at 6 hours
- timeFrame
- 6 hours After surgery
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * patients scheduled for an radical mastectomy and implant reconstruction surgery * Patients with American Society of Anesthesiologists (ASA) physical status I-II, * aged 18-70 years Exclusion Criteria: * coagulation disorders, * known allergy to study drugs, * obesity (body mass index \> 35 kg/m2), * infection at the injection site, * chronic opioid consumption, and an inability to use patient-controlled analgesia (PCA) device, * patient refuse
References
Publications (1)
- Source
- PubMed (NLM)
- Dataset
- PubMed E-utilities
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
Dandan Ling, Shiyou Wei, Qianping He et al. · Ann Med · Dec 1, 2026 · PMID 42686359 pubmed
- DERIVEDLing D, Wei S, He Q, Li Y, Xu Q, Jiao W, Zhang J. Effects of erector spinae plane block on postoperative pain in patients undergoing implant-based breast reconstruction for breast cancer: a randomized controlled trial. Ann Med. 2026 Dec;58(1):2722439. doi: 10.1080/07853890.2026.2722439. Epub 2026 Sep 2. PMID 42686359